UBS Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

UBS Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,000	Closed	-$659K	–	10859
2025 Q3	$659K	Buy	+5,000	New	+$600K	﹤0.01%	5892
2018 Q3	–	Sell	-141,400	Closed	-$24.4M	–	8111
2018 Q2	$24.4M	Buy	+141,400	New	+$23.1M	0.01%	1047
2017 Q1	–	Sell	-52,500	Closed	-$5.72M	–	7786
2016 Q4	$5.72M	Buy	52,500 +20,000	+62%	+$2.23M	﹤0.01%	1974
2016 Q3	$3.95M	Buy	+32,500	New	+$4.38M	﹤0.01%	2243
2016 Q1	–	Sell	-700	Closed	-$98K	–	7891
2015 Q4	$98K	Hold	700	–	–	﹤0.01%	5229
2015 Q3	$93K	Hold	700	–	–	﹤0.01%	5289
2015 Q2	$123K	Sell	700 -2,400	-77%	-$431K	﹤0.01%	5241
2015 Q1	$536K	Sell	3,100 -4,600	-60%	-$789K	﹤0.01%	4085
2014 Q4	$1.26M	Buy	+7,700	New	+$1.28M	﹤0.01%	3384

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

UBS Group's JAZZ Position: Q2 2026 in Review

UBS Group increased its Jazz Pharmaceuticals (JAZZ) stake by 112% in Q2 2026, buying an estimated $87.6M and bringing the position to 756,865 shares worth $182M. The position accounts for 0.02% of the portfolio, ranked #722.

UBS Group first reported a position in JAZZ in Q4 2014 and has held it in 47 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

UBS Group held 756,865 shares of Jazz Pharmaceuticals worth $182M as of Q2 2026.
UBS Group bought 399,662 Jazz Pharmaceuticals shares in Q2 2026, an estimated $87.6M.
Jazz Pharmaceuticals made up 0.02% of UBS Group's portfolio in Q2 2026, its #722 holding.
UBS Group first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.